La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Lifecore Biomedical a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Lifecore Biomedical..

Lifecore Biomedical (NASDAQ:LFCR) Azioni, Catena delle Opzioni

Lifecore Biomedical

Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that offers differentiated capabilities in the development, filling, and finishing of complex sterile injectable pharmaceutical products in syringes and vials. It manufactures injectable-grade Hyaluronic Acid. Lifecore recognizes revenue in two different product categories, CDMO and fermentation.

Lifecore Biomedical Inc

Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENT#NASDAQ">CENT</a>) announced its Q4 earnings on Monday, November 25, 2024 at 04:02 PM.
Here's a breakdown of the earnings report.
<h3>Earnings</h3>
Central Garden &amp; Pet beat estimated earnings by 10.0%, reporting an EPS of $-0.18 versus an estimate of $-0.2.
Revenue was down $80.66 million from the same period last year.
<h3>Overview of Past Earnings</h3>
Last quarter the company beat on EPS by $0.11 which was followed by a 6.0% increase in the share price the next day.
Here's a look at Central Garden &amp; Pet's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.21</td>
<td>0.80</td>
<td>-0.14</td>
<td>0.06</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.32</td>
<td>0.99</td>
<td>0.01</td>
<td>0.08</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>1.00B</td>
<td>887.42M</td>
<td>619.95M</td>
<td>735.32M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>996.35M</td>
<td>900.09M</td>
<td>634.53M</td>
<td>750.15M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Central Garden &amp; Pet <a href="https://www.benzinga.com/quote/CENT/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

CENT

Recap: Central Garden & Pet Q4 Earnings

Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENTA#NASDAQ">CENTA</a>) just disclosed its Q4 earnings on Monday, November 25, 2024 at 04:02 PM.
Here's a brief overview of the earnings report.
<h3>Earnings</h3>
Central Garden &amp; Pet beat estimated earnings by 18.0%, reporting an EPS of $-0.18 versus an estimate of $-0.22.
Revenue was down $80.66 million from the same period last year.
<h3>Previous Earnings Records</h3>
The company beat on EPS by $0.02 in the last quarter, resulting in a 0.0% increase share price change the following day.
Here's a look at Central Garden &amp; Pet's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.20</td>
<td>1.21</td>
<td>0.80</td>
<td>0.76</td>
<td>-0.14</td>
<td>-0.14</td>
<td>0.06</td>
<td>0.06</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.32</td>
<td>1.32</td>
<td>0.99</td>
<td>0.99</td>
<td>0.01</td>
<td>0.01</td>
<td>0.08</td>
<td>0.08</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>1.00B</td>
<td>1.00B</td>
<td>887.42M</td>
<td>883.42M</td>
<td>619.95M</td>
<td>619.95M</td>
<td>735.32M</td>
<td>735.32M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>996.35M</td>
<td>996.35M</td>
<td>900.09M</td>
<td>900.09M</td>
<td>634.53M</td>
<td>634.53M</td>
<td>750.15M</td>
<td>750.15M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Central Garden &amp; Pet <a href="https://www.benzinga.com/quote/CENTA/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CENTA

Earnings Breakdown: Central Garden & Pet Q4

Fourth Quarter of Fiscal Year 2025 Outlook
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">(in millions, except per share data)</td>
<td colspan="7" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net sales</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">250.0</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">+/-</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$5.0</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Non-GAAP Financial Measures</td>
<td colspan="3" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Gross margin</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">52.8</td>
<td colspan="1" rowspan="1">%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">+/-</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">50 bps</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Operating expenses, net</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">82.8</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">+/-</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$1.0</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Operating income</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">49.2</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">+/-</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$2.8</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Operating margin</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">19.7</td>
<td colspan="1" rowspan="1">%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">+/-</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">70 bps</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Interest expense, net</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">19.0</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Normalized tax rate</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">15</td>
<td colspan="1" rowspan="1">%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Diluted earnings per share</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">0.32</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">+/-</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$0.03</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">56.9</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">+/-</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$2.8</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA margin</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">22.8</td>
<td colspan="1" rowspan="1">%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">+/-</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">70 bps</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Diluted share count</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">80.0</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
See "Non-GAAP Financial Measures" below for additional information about our non-GAAP financial results.
The Company is unable to include a reconciliation of forward-looking non-GAAP results to the corresponding GAAP measures as this is not available without unreasonable efforts due to the high variability and low visibility with respect to the impact of transaction, integration and restructuring expenses, share-based awards, amortization of acquisition-related intangible assets and other items that are excluded from these non-GAAP measures. The Company expects the variability of the above charges to have a potentially significant impact on its GAAP financial results.

News

Guidance

SMTC

Semtech Sees Q4 EPS $0.32 +/- $0.03 Vs $0.27 Est.; Revenue $250M +/- $5M Vs $242.03M Est.

Nehama served on the Board of Directors and as the Company's Chairman of the Board since March 2008 and is a controlling shareholder of the Company.
Sheizaf will serve as a director until the Company's 2025 annual general meeting, at which he can be nominated for reappointment to the Company's Board of Directors.

Management

ELLO

Ellomay Capital Says Chairman Shlomo Nehama Has Decided To Resign From Board; Ben Sheizaf Named As Board Member And Chairman

Semtech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) reported quarterly earnings of $0.26 per share which beat the analyst consensus estimate of $0.23 by 13.04 percent. This is a 1200 percent increase over earnings of $0.02 per share from the same period last year. The company reported quarterly sales of $236.80 million which beat the analyst consensus estimate of $232.06 million by 2.04 percent. This is a 17.87 percent increase over sales of $200.90 million the same period last year.

Earnings Beats

Semtech Q3 Adj $0.26 Beats $0.23 Estimate, Sales $236.80M Beat $232.06M Estimate

<ul>
<li>In 2020, Alibaba Group Holding Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) prepared for the record-breaking IPO of its affiliate, Ant Group, poised to revolutionize financial technology.</li>
<li>Just days before the launch, regulators revealed that Ant had bypassed key banking laws to expand its services.</li>
<li>The IPO, valued at $35 billion, was abruptly suspended, causing Alibaba's stock to plummet 13% in a single day.</li>
<li>Shortly after, the State Administration for Market Regulation launched an antitrust investigation into Alibaba's monopolistic practices.</li>
<li>Investors alleged that Alibaba misled them about regulatory risks tied to Ant Group, its ownership structure, and lending activities.</li>
<li>Alibaba has agreed to a $433.5 million settlement with investors to resolve these claims. Affected investors can now <a href="https://11thestate.com/cases/alibaba-investor-settlement">file a claim</a> to receive their payouts.</li>
</ul>
Overview
In July 2020, Ant Group announced plans for a record-breaking $35 billion IPO, poised to drive significant growth for Alibaba Group Holding Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>), which held a 33% stake. However, regulatory concerns over Ant's business model, ownership structure, and compliance with new fintech rules led to the IPO's abrupt suspension in November, just days before its launch. The fallout caused Alibaba's shares to plummet, erasing billions in market value, and triggered an antitrust investigation into its monopolistic "Choose One of Two" practices. In response, investors filed a class-action lawsuit, accusing Alibaba of failing to disclose critical regulatory risks. Recently, Alibaba agreed to pay $433.5 million to affected shareholders to settle this lawsuit.
SAMR's Crackdown on Alibaba: Legal and Regulatory Implications
As Alibaba's market dominance and access to vast consumer data grew, the Chinese government expressed rising concerns about its economic impact. In response, the SAMR introduced new anti-monopoly regulations on September 1, 2019, targeting practices by powerful companies like Alibaba. 
On November 5, SAMR convened a meeting with around twenty major e-commerce firms, warning that practices like "Choose One of Two" were illegal and must stop.&nbsp;
While Alibaba did not deny using such practices, it dismissed the criticism as "slander" and "malicious hype" in a press statement. Under growing regulatory pressure, however, the company eventually committed to compliance, acknowledging potential scrutiny for future violations.
Despite the clear warnings, Alibaba continued its anti-competitive behavior. In November 2020, the government introduced new regulations specifically targeting monopolistic behavior in the internet industry, with Alibaba as a primary focus. 
This announcement triggered a sharp 9% drop in Alibaba's share price on November 10, 2020. By December, SAMR launched a formal investigation, which ultimately found Alibaba guilty and resulted in a record $2.8 billion fine.&nbsp;
Political Risk and the Hidden Investors Behind Ant&#8217;s IPO
Ant Group was spun off from Alibaba in 2011. Jack Ma controlled 50.5% of Ant's shares, while Alibaba held a 33% stake.&nbsp;
On July 20, 2020, Alibaba announced Ant&#8217;s IPO, aiming to raise a record $35 billion with a $300 billion valuation, sparking excitement among investors, as Alibaba's stake could be worth over $100 billion.&nbsp;
However, the enthusiasm was short-lived, as the company revealed in November 2020 that the IPO had been abruptly suspended.
The suspension was largely driven by Ant's attempt to bypass financial regulations. Although operating as a financial services company, Ant positioned itself as a tech firm to avoid traditional banking rules. Its high-risk lending activities, with leverage ratios of 50-60 times, raised serious concerns among regulators. In response, China introduced new rules in September 2020, requiring financial holding companies like Ant to maintain higher capital levels, further intensifying scrutiny. Jack Ma's criticism of regulators in an October speech further fueled tensions.
Another major risk to the IPO was the hidden identities of private investors whose interests conflicted with those of Chinese President. These investors concealed their ownership through complex and opaque investment structures. Jack Ma was reportedly aware of the political risks tied to these undisclosed ownership interests but failed to address them transparently. When the Chinese government uncovered the identities of these investors during an investigation prior to the Ant IPO, it decided to halt the offering entirely.
As a result of the undisclosed information, the share price of Alibaba dropped from $310 on November 2, 2020, to $222 on December 24, 2020, indicating a total fall of 29%.&nbsp;
Following these events, investors accused Alibaba of failing to disclose the regulatory risks tied to Ant Group and its monopolistic practices, leading to a lawsuit against the company.
Resolving the Case
To resolve the lawsuit from investors, Alibaba has agreed to a cash settlement of $433.5 million. If you invested in Alibaba, you may be eligible to <a href="https://11thestate.com/cases/alibaba-investor-settlement">claim a portion</a> of this settlement to recover your losses.
Despite these efforts, Alibaba&#8217;s stock remains below its peak, trading at $85. 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="355" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/25182447/image-3-1024x355.png" alt="" class="wp-image-3603" style="width:624px" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/25182447/image-3-1024x355.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/25182447/image-3-300x104.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/25182447/image-3-768x266.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/25182447/image-3.png 1036w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
In August 2024, China's market regulator announced that Alibaba had completed three years of "rectification" for monopolistic behavior. Alibaba called the announcement a "new starting point for development" and pledged to continue fostering the healthy growth of the platform economy.

Markets

General

BABA

The Fall of Ant Group's IPO: Alibaba's Missteps, Legal Battles, and a $433.5M Settlement

Athena Technology Acquisition Corp. II (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATEK#NYSE">ATEK</a>, ATEK, ATEK WS))) ("ATEK" or the "Company") received an official notice of noncompliance (the "NYSE American Notice") from NYSE Regulation ("NYSE") stating that the Company is not in compliance with NYSE American continued listing standards due to the failure to timely file the Company's Form 10-Q for the quarter ended September 30, 2024 (the "Delinquent Report") by the filing due date of November 19, 2024 (the "Filing Delinquency").
The Company intends to file the Delinquent Report in the near future, however, there is currently no anticipated date for when such Filing Delinquency will be cured via the filing of the Delinquent Report. The Company expects, however, to regain compliance with the NYSE American continued listing standards once the Delinquent Report has been filed. In the interim, the NYSE American Notice has no immediate effect on the listing or trading of the Company's Class A common stock listed on NYSE American. There can be no assurance that the Company will ultimately regain and remain in compliance with all applicable NYSE American listing standards.

ATEK

Athena Technology Acquisition Corp. II Announces Receipt Of Notice Of Non-Compliance With NYSE American Continued Listing Requirements

The Company previously presented its plan to file all delinquent periodic reports with the SEC, including the Form 10-Q for the period ended September 30, 2024, and requested an extension to do so at a hearing before the Nasdaq Hearings Panel. The Panel has not yet issued its decision following the hearing.

Real Good Food Company Gets Additional Delinquency Notice From Nasdaq Listing Qualifications Staff

Leslies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LESL#NASDAQ">LESL</a>) reported quarterly earnings of $0.02 per share which missed the analyst consensus estimate of $0.11 by 81.82 percent. The company reported quarterly sales of $397.900 million which missed the analyst consensus estimate of $405.197 million by 1.80 percent. This is a 7.97 percent decrease over sales of $432.370 million the same period last year.

Earnings Misses

LESL

Leslies Q4 2024 Adj. EPS $0.02 Misses $0.11 Estimate, Sales $397.900M Miss $405.197M Estimate

Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) reported quarterly losses of $(1.36) per share. This is a 2.26 percent decrease over losses of $(1.33) per share from the same period last year. The company reported $14.61 million in sales this quarter. This is a 22.84 percent decrease over sales of $18.93 million the same period last year.

ENTA

CORRECTION: Enanta Pharma Q4 EPS $(1.36) Down From $(1.33) YoY, Sales $14.61M Down From $18.93M YoY

The earnings results for Blue Bird (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLBD#NASDAQ">BLBD</a>) for Q4 were made public on Monday, November 25, 2024 at 04:00 PM.
Here's a comprehensive overview of the announcement.
<h3>Earnings</h3>
Blue Bird missed estimated earnings by -16.0%, reporting an EPS of $0.77 versus an estimate of $0.92.
Revenue was up $47.25 million from the same period last year.
<h3>Previous Earnings Records</h3>
The company beat on EPS by $0.4 in the last quarter, resulting in a 0.0% increase share price change the following day.
Here's a look at Blue Bird's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.51</td>
<td>0.48</td>
<td>0.37</td>
<td>0.48</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.91</td>
<td>0.89</td>
<td>0.91</td>
<td>0.66</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>328.60M</td>
<td>298.41M</td>
<td>275.13M</td>
<td>290.11M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>333.37M</td>
<td>345.92M</td>
<td>317.66M</td>
<td>302.96M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Blue Bird <a href="https://www.benzinga.com/quote/BLBD/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BLBD

Blue Bird: Q4 Earnings Insights

The Q4 earnings report for Woodward (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>) was released on Monday, November 25, 2024 at 04:00 PM.
Here's what investors need to know about the latest announcement.
<h3>Earnings</h3>
Woodward beat estimated earnings by 13.0%, reporting an EPS of $1.41 versus an estimate of $1.25.
Revenue was up $77.42 million from the same period last year.
<h3>Historical Earnings Summary</h3>
The company beat on EPS by $0.12 in the last quarter, resulting in a 17.0% drop share price change the following day.
Here's a look at Woodward's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.51</td>
<td>1.32</td>
<td>1.10</td>
<td>1.31</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.63</td>
<td>1.62</td>
<td>1.45</td>
<td>0.84</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>853.82M</td>
<td>807.00M</td>
<td>748.29M</td>
<td>765.35M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>847.69M</td>
<td>835.34M</td>
<td>786.73M</td>
<td>777.07M</td>
</tr>
</tbody>
</table>

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Guidance</h3>
Woodward management provided guidance for FY 2025, expecting earnings between $5.75 and $6.25 per share.
To track all earnings releases for Woodward <a href="https://www.benzinga.com/quote/WWD/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Woodward Earnings Review: Q4 Summary

Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) announced its Q4 earnings on Monday, November 25, 2024 at 04:01 PM.
Here's a breakdown of the earnings report.
<h3>Earnings</h3>
Enanta Pharma beat estimated earnings by 4.0%, reporting an EPS of $-1.36 versus an estimate of $-1.41.
Revenue was down $4.33 million from the same period last year.
<h3>Performance in Previous Earnings</h3>
During the previous quarter, the company beat on EPS by $0.38, leading to a 1.0% increase share price change the next day.
Here's a look at Enanta Pharma's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.45</td>
<td>-1.33</td>
<td>-1.19</td>
<td>-2</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.07</td>
<td>-1.47</td>
<td>-1.58</td>
<td>-1.33</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>17.18M</td>
<td>16.52M</td>
<td>21.28M</td>
<td>17.50M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>17.97M</td>
<td>17.05M</td>
<td>18.00M</td>
<td>18.93M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Enanta Pharma <a href="https://www.benzinga.com/quote/ENTA/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Breakdown: Enanta Pharma Q4

As of September 30, 2024, Alector has $457.2 million in cash, cash equivalents, and investments, which the company continues to expect will provide runway through 2026. Alector plans to provide guidance for 2025 during its fourth-quarter and full-year earnings conference call.

ALEC

Alector Expects Cash & Equivalents To Provide Runway Through 2026

WIIM

Agilent Technologies shares are trading lower after the company provided Q1 and FY25 adjusted EPS and revenue guidance below analyst expectations.

Central Garden & Pet shares are trading lower after the company reported Q4 sales that missed analyst estimates, despite better-than-expected adjusted EPS.

The term "metaverse" was one of the top trends in 2021 with companies and cryptocurrencies related to the term seeing soaring valuations. While interest in the metaverse has fallen off in recent years, two cryptocurrencies with ties to the metaverse were among the <a href="https://www.benzinga.com/money/top-metaverse-coins">top gainers of the past week.</a>
What Happened: The Sandbox (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sand/usd">SAND</a>) and Decentraland (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/mana/usd">MANA</a>) cryptocurrencies are among the biggest movers of the last week, gaining 107% and 57%, respectively, over the last seven days, which comes as interest in the metaverse <a href="https://www.benzinga.com/news/events/24/11/42172802/nfts-metaverse-derided-rightly-but-experts-see-bright-future-ahead" target="_blank" rel="noopener">could be growing once again.</a>
The two coins are connected to virtual worlds and were high performers in 2021 and 2022 as interest in virtual land and metaverse-related companies and cryptocurrencies soared.
While the prices of the coins are down sharply from all-time highs set in November 2021, the recent gains have the coins hitting new levels not seen in some time.
The Sandbox coin is up 27% over the last day to $0.7294, making it one of the top gainers in the last 24 hours. The coin has traded between $0.2098 and $0.8493 over the last year, with the yearly high recently hit in the past week. The all-time high for the coin is $8.44, set on Nov. 25, 2021.
The Decentraland coin is up 11% over the last day to $0.6532, making it one of the top gainers in the last 24 hours. The coin has traded between $0.2181 and $0.8185 over the last year. Over the past week, it hit new monthly highs of $0.7731. The all-time high for the coin is $5.90, set on Nov. 25, 2021.
Investors who bought the metaverse-related coins in 2021 could have generated a nice profit throughout the year and into 2022. Here's a look at their stake if they held.
Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41908812/if-you-invested-100-in-dogecoin-when-the-meme-coin-launched-heres-how-much-youd-have-today">If You Invested $100 In Dogecoin When The Meme Coin Launched, Here&#8217;s How Much You&#8217;d Have Today</a>
Investing $1,000 in SAND, MANA: The Sandbox coin&nbsp;<a href="https://coinmarketcap.com/currencies/the-sandbox/" target="_blank" rel="noreferrer noopener">traded&nbsp;</a>at a high of $0.0379 on Jan. 1, 2021. A $1,000 investment in SAND on the first day of the year could have bought 26,385.22 SAND coins.
The $1,000 investment would be worth $19,245.38 today based on a current price of $0.7294, up 1,824.5% since the start of 2021.
The Decentraland coin&nbsp;<a href="https://coinmarketcap.com/currencies/decentraland/" target="_blank" rel="noreferrer noopener">traded&nbsp;</a>at a high of $0.0839 on Jan. 1, 2021. A $1,000 investment in MANA on the first day of the year could have bought 11,918.95 MANA coins.
The $1,000 investment would be worth $7,785.46 today based on a current price of $0.6532, up 678.5% since the start of 2021.
What's Next: The metaverse was a big topic in 2021 with the launch of virtual land from several companies, the launch of the Roundhill Ball Metaverse ETF and <a href="https://www.benzinga.com/general/education/24/10/41163360/if-you-invested-1-000-in-facebook-stock-when-mark-zuckerberg-changed-name-to-meta-heres-how-muc">the announced rebrand</a> of Facebook to Meta Platforms.
Tesla CEO Elon Musk <a href="https://www.benzinga.com/markets/cryptocurrency/21/12/24718726/is-the-metaverse-a-marketing-buzzword-or-multitrillion-dollar-opportunity-elon-musk-cathie">called the metaverse</a> a "marketing buzzword" previously.
Ark Invest CEO Cathie Wood took the other side and said the metaverse was in the early stages of development at the time.
"It's a big idea that will probably infiltrate – just like technology is, anyway – every sector in ways that we cannot even imagine right now," Wood said.
She said the metaverse could be a multitrillion-dollar opportunity, a stark contrast from Musk saying the metaverse is a marketing buzzword.
Fast-forward to today, and skepticism around the metaverse has grown, with some use cases losing their luster and excitement waning in recent years. Yet, metaverse and gaming tokens have recently surged as top crypto gainers, sparking renewed investor interest in the sector&#8217;s potential revival.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42146874/if-you-invested-1000-in-solana-when-sam-bankman-fried-was-arrested-heres-how-much-youd-have-today">If You Invested $1,000 In Solana When Sam Bankman-Fried Was Arrested, Here&#8217;s How Much You&#8217;d Have Today</a></li>
</ul>
This article was previously published by Benzinga and has been updated.
Photo: Koshiro K/Shutterstock.com

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$MANA

$SAND

If You Invested $1,000 In The Sandbox And Decentraland Coins On Jan. 1, 2021, Here's How Much You'd Have Now

Alector Says It Is Reducing Its Workforce By Approximately 17%, Stopping Long-term Extension Study Based Upon AL002 INVOKE-2 Phase 2 Trial Results

Zoom shares are trading lower following Q3 earnings.

Alector shares are trading lower after the company announced that the INVOKE-2 Phase 2 clinical trial evaluating the safety and efficacy of AL002 in individuals with early Alzheimer's disease failed to meet its primary endpoint.

Lifecore Biomedical GAAP EPS of -$0.53, revenue of $24.7M

Lifecore (LFCR) Biomedical announced that it has appointed Thomas Guldager as vice president, operations. An experienced pharmaceutical industry pr...

Lifecore appoints Guldager as vice president, operations

Lifecore (LFCR) Biomedical announced that it will host a virtual investor day on Thursday, November 21, 2024, prior to market open. The event will ...

Lifecore to host virtual investor day on November 21

Craig-Hallum analyst Matt Hewitt maintained a Buy rating on Lifecore Biomedical (LFCR – Research Report) today. The company's shares closed yesterd...

Craig-Hallum Sticks to Their Buy Rating for Lifecore Biomedical (LFCR)

Greenhaven Road Capital Q3 2024 Investor Letter

Lifecore Biomedical: Finally A 'Pure Play' CDMO Business

Lifecore Biomedical ( ($LFCR) ) just unveiled an announcement. Lifecore Biomedical, Inc., a leader in complex injectables, is poised for sustainabl...

Lifecore Biomedical Plans Strategic Growth and Transformation

In a report released today, Michael Petusky from Barrington maintained a Hold rating on Lifecore Biomedical (LFCR – Research Report). The company's...

Barrington Remains a Hold on Lifecore Biomedical (LFCR)

Craig-Hallum analyst Matthew Hewitt raised the firm's price target on Lifecore (LFCR) to $10 from $8 and keeps a Buy rating on the shares. Lifecore...

Lifecore price target raised to $10 from $8 at Craig-Hallum

Craig-Hallum analyst Matt Hewitt maintained a Buy rating on Lifecore Biomedical (LFCR – Research Report) today and set a price target of $10.00. Th...

Craig-Hallum Remains a Buy on Lifecore Biomedical (LFCR)

CLBT

CTLT

HGTY

LFCR

SBUX

Press Releases

Lifecore Biomedical Selected by Lindy Biosciences to Support Process Development and Commercial Scale-Up for Innovative Microglassification Formulation Technology

Biotech

Lifecore Biomedical to Report Financial Results for First Quarter of Fiscal 2025 Prior to Market Open on October 4, 2024

Financing

Lifecore Biomedical Raises $24.3 Million in Private Placement of Common Stock

Lifecore Biomedical Reports First Quarter of Fiscal 2025 Financial Results and Provides Corporate Update

Legal

Johnson Fistel LLP Investigates Lifecore Biomedical, Inc's Directors and Officers for Breach of Fiduciary Duties and Encourages Long Term Shareholders to Reach Out for Their Options

Comments

Lifecore Biomedical

Lifecore Biomedical (LFCR) Opzioni

Lifecore Biomedical (NASDAQ:LFCR) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO